,N'-tetramethyluronium hexafluorophosphate MALDI-Tof -matrix-assisted laser desorption/ionization time-of-flight MeCN -acetonitrile MS -mass spectrometry PBS -phosphate-buffered saline PTX -paclitaxel RP-HPLC -reverse-phase high performance liquid chromatography TCEP -tris(carboxyethyl)phosphine TFA -trifluoroacetic acid 
S1.2 Materials and methods
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S1.4 Drug loading calculations
The drug loading of the drug amphiphiles is given as the drug weight as a percentage of the total molecular weight:
where M Drug is the exact mass of the drug (CPT or PTX) and M DA is the exact mass of the drug amphiphile 
S1.5 Drug amphiphile concentration assay
To determine the CPT concentration of the purified drug amphiphiles, a TCEP reduction assay was 
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S1.6 Reactivity of CPT-Cys-Sup35 and PTX-Cys-Sup35
To demonstrate that the conjugates were isolated as free and reactive thiols, they were tested for their ability to undergo disulfide exchange, both with themselves ( Fig. S5 ) and with other reactive species (Fig.   S5 ). CPT-Cys-Sup35 was dissolved initially dissolved in water and immediately analyzed by HPLC,
showing that the dominant species was still the isolated product (black trace in Fig. S5) . After 1 h, the formation of dCPT-Sup35 and CPT-buSH could be seen (blue trace in Fig. S5 ), indicating that the conjugate's free thiol was acting as a nucleophile toward CPT-Cys-Sup35. Diluting a portion of the solution into PBS, it was clear that the higher pH enabled the thiol to become more active as the extent of reaction was more pronounced (red trace in Fig. S5 ), giving the disulfide, (CPT-buS) 2 as the dominant species. These observations are as expected given thiols become more reactive at higher pH, with the aqueous and PBS solutions having pH values of ~5 and 7.4, respectively.
Fig. S5 HPLC analysis of an aqueous solution of CPT-Cys-Sup35 upon initial dissolution (black) and after 1 h (blue).
The aqueous solution was also diluted two times into PBS and monitored after 1 h. Both solutions shows that the CPT-Cys-Sup35 will scramble to give dCPT-Sup35, CPT-buSH and (CPT-buS)2, with the speed of reaction determined by the solution pH (~5 for water and 7.4 for PBS). Chromatograms are normalized with respect to the most intense signal.
A DMSO solution of PTX-Cys-Sup35 was allowed to react with the activated disulfide, CPT-buSS-Pyr, giving the hetero-DDA, CPT-PTX-Sup35, as the major product (Fig. S6 ). This and the previous S8 experiment both illustrate the potential usefulness of a singly reacted di-thiol containing species, as it can be isolated and then used as a reagent to form other dual drug amphiphiles as desired.
Fig. S6 HPLC analysis of a DMSO solution of PTX-Cys-Sup35
to which was added CPT-buSS-Pyr, indicating that the conjugate remains active towards directed disulfide exchange and allows formation of the CPT-PTX-Sup35 dual drug amphiphile. This suggests that the singly reacted species can be isolated and used as a reagent in its own right for the reaction with other activated drug molecules. 
S2. Self-Assembly Characterization
S2.1 Effect of dilution into PBS on CPT-PTX-Sup35 assembly
S2.2 Cryo-TEM images of dCPT-Sup35
S2.3.2 Critical aggregation concentration (CAC) determination of CPT-PTX-Sup35
The CAC values for CPT-PTX-Sup35 and dCPT-Sup35 were determined using a Nile Red encapsulation method. Briefly, from a 1 mM stock of CPT-PTX-Sup35 or dCPT-Sup35 in water that had been aged for at least 2 days, a series of dilutions in pure water were prepared, ranging from 0.5 nM to 200 M. To 250 L of each solution, was added 2.5 mL of a 1 mM solution of Nile Red in acetone.
The acetone was then allowed to evaporate and the solution was equilibrated overnight. The fluorescence spectrum of each solution was recorded using a Fluorolog spectrofluorometer (Horiba Jobin Yvon Inc., Edison, NJ), exciting at 550 nm and collecting the emission intensity between 580 and 720 nm. To obtain the CAC value, the data from the 640 emission was plotted against the concentration on a log scale, with the value given by the intersection of the two linear segments (Fig. S10) . The experiment was repeated to verify the trend. 
S2.3.3 Hydrolytic stability of the assembled structures
The hydrolytic stability of the assembled DAs was determined by analysis of 100 M and 1 mM solutions after 2 weeks of aging at room temperature.
Fig. S11
Hydrolytic stability of dCPT-Sup35 (a), CPT-PTX-Sup35 (b), and dPTX-Sup35 (c) at 100 M (red trace) and 1 mM (black trace) in pure water after 2 weeks aging at room temperature. All solutions were monitored using a wavelength of 220 nm.
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S3. Drug Release HPLC Protocol
The degradation of CPT-PTX-Sup35 was monitored by RP-HPLC using the following conditions: 237 nm detection wavelength; 1 ml/min flow rate; mobile phase was 0.1% aqueous TFA (A) and acetonitrile containing 0.1% TFA; gradient is given in Table S1 . The concentrations of CPT-PTX-Sup35, CPT and PTX were determined by measuring the area of the respective peaks and comparing against a calibration curve for each species. PTX-CPT-Sup35 was diluted with fresh medium and incubated with cells immediately to achieve final conjugate concentrations. Medium containing the same concentration of PTX, CPT or dPTX-Sup35 were also used to incubate the cells, with non-treated cells (solvent only) as the control group. After 48 h incubation, the cell viability was determined using the SRB method according to the manufacturer's protocol (TOX-6, Sigma, St. Louis, MO). 
S4.2 Cytotoxicity results
S4.3 dCys-Sup35 cytotoxicity
Fig. S14 Cytotoxicity of dCys-Sup35 against KB-3-1 (a) and KB-V1 (b) cervical cancer cells. Cell viability was determined by SRB assay after 48 h incubation with the appropriate drug-containing media. Data are given as mean ± s.d. (n = 3).
